PLANTATION, Fla., April 21,
2022 /CNW/ - Akumin Inc. (NASDAQ: AKU) (TSX:
AKU) ("Akumin"), a premier provider of outpatient medical services
in the U.S., announced today that it has filed a registration
statement, which includes a management proxy circular, with the
Securities and Exchange Commission ("SEC") pursuant to which Akumin
proposes to provide its board of directors (the "Board") with the
discretion to change Akumin's jurisdiction of incorporation from
the province of Ontario to the
State of Delaware in the United States of America through the
adoption of a certificate of corporate domestication and a new
certificate of incorporation (the "Domestication"). Following SEC
clearance of Akumin's registration statement, Akumin will hold a
meeting of shareholders seeking shareholder approval to provide the
Board with the discretion to change Akumin's jurisdiction of
incorporation. Details of Akumin 's meeting of shareholders
will be announced at a later date. If approved by the shareholders,
the Domestication would only be implemented upon a determination by
the Board that it is in the best interest of Akumin and the
shareholders at that time.
Akumin believes the Domestication would reduce operating
expenses and transactional inefficiencies that currently result
from being subject to Canadian corporate laws despite having no
operations in Canada.
Riadh Zine, Chairman and Chief
Executive Officer of Akumin, stated, "Changing our jurisdiction
would reduce Akumin's organizational complexity and reduce our
administrative costs. We chose the State of Delaware to be our domicile because
of its favorable corporate environment which would help Akumin
compete effectively in raising the capital necessary for it to
continue to implement its strategic plan."
About Akumin
Akumin is a national partner of choice for U.S. hospitals,
health systems and physician groups, with comprehensive solutions
addressing outsourced radiology and oncology service line needs.
Akumin provides: (1) fixed-site outpatient diagnostic imaging
services through a network of more than 200 owned and/or operated
imaging locations; and (2) outpatient radiology and oncology
services and solutions to approximately 1,000 hospitals and health
systems across 46 states. By combining clinical and operational
expertise with the latest advances in technology and information
systems, Akumin facilitates more efficient and effective diagnosis
and treatment for patients and their providers. Akumin's imaging
procedures include MRI, CT, positron emission tomography (PET and
PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and
other interventional procedures; cancer care services include a
full suite of radiation therapy and related offerings. For more
information, visit www.akumin.com and
www.alliancehealthcareservices-us.com.
For further information:
R. Jeffrey White
Investor Relations
1-866-640-5222
jeffrey.white@akumin.com
Forward-Looking Information
Certain information in this press release constitutes
forward-looking information. In some cases, but not necessarily in
all cases, forward-looking information can be identified by the use
of forward-looking terminology such as "plans", "targets",
"expects" or "does not expect", "is expected", "is positioned",
"estimates", "intends", "assumes", "anticipates" or "does not
anticipate" or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances contain forward-looking information. Statements
containing forward-looking information are not historical facts but
instead represent management's expectations, estimates and
projections regarding future events.
Forward-looking information is necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by Akumin as of the date of this press release, are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, level of activity,
performance or achievements to be materially different from those
expressed or implied by such forward-looking information,
including, but not limited to, the factors described in greater
detail in the "Risk Factors" section of Akumin's Annual Report on
Form 10-K for the fiscal year ended December
31, 2021, filed with the SEC on March
16, 2022, as amended by Amendment No. 1 to Form 10-K, filed
with the SEC on April 12, 2022 (the
"2021 Annual Report"), which is available at www.sedar.com and
www.sec.gov. These factors are not intended to represent a complete
list of the factors that could affect Akumin; however, these
factors should be considered carefully. There can be no assurance
that such estimates and assumptions will prove to be correct. The
forward-looking statements contained in this press release are made
as of the date of this press release, and Akumin expressly
disclaims any obligation to update or alter statements containing
any forward-looking information, or the factors or assumptions
underlying them, whether as a result of new information, future
events or otherwise, except as required by law.
Additional Information
Akumin has filed a registration statement (including a
prospectus) on Form S-4 with the SEC. After the registration
statement has been declared effective by the SEC, a definitive
prospectus will be mailed to each shareholder of common stock
entitled to vote at the meeting in connection with the proposed
transaction. INVESTORS ARE URGED TO READ THE PROSPECTUS AND
ANY OTHER DOCUMENTS RELATING TO THE TRANSACTION TO BE FILED WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
PROPOSED TRANSACTION. You may get these documents, when available,
for free by visiting EDGAR on the SEC Website at www.sec.gov or by
visiting Akumin's website at www.akumin.com.
Additional information about Akumin, including a copy of its
2021 Annual Report and filings on Form 8-K, can be accessed on the
Canadian Securities Administrators' website at www.sedar.com, on
the EDGAR section of the U.S. Securities and Exchange Commission's
website at www.sec.gov or through Akumin 's website at
www.akumin.com.
View original
content:https://www.prnewswire.com/news-releases/akumin-announces-filing-of-registration-statement-in-connection-with-change-of-jurisdiction-of-incorporation-301529959.html
SOURCE Akumin Inc.